Valuation: C4 Therapeutics, Inc.

Market Cap 428M 371M 347M 317M 596M 40.81B 606M 4.07B 1.59B 20.43B 1.61B 1.57B 68.15B P/E 2026 *
-4.89x
P/E 2027 * -3.91x
Enterprise Value 428M 371M 347M 317M 596M 40.81B 606M 4.07B 1.59B 20.43B 1.61B 1.57B 68.15B EV / Sales 2026 *
22.6x
EV / Sales 2027 * 22.4x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+1.16%
1 week+6.33%
Current month+10.61%
1 month-1.81%
3 months+21.43%
6 months+110.34%
Current year+101.53%
1 week 3.58
Extreme 3.58
4
1 month 3.36
Extreme 3.36
4.05
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Fiscal year

Chief Technology Officer

22,722 0.0206%
01/07/26 Free

Director

3,341 0.0030%
01/07/26 Free

Founder

2,650 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%+6.33%+71.84%+13.88% 428M
-2.14%+0.39%+3.22%+14.04% 49.54B
+1.03%+4.42%+484.32%+586.77% 44.06B
-0.97%+8.02%+22.80%+73.32% 40.85B
-1.42%+1.75%+29.19%+9.11% 40.14B
+4.73%+13.29%+27.76%+54.22% 34.17B
-0.65%+2.08%+30.64%+125.89% 16.9B
-0.89%+3.99% - - 16.78B
-0.92%-0.46%+3.86%+20.29% 14B
+0.23%+8.79%+85.69%+30.77% 13.46B
Average +0.04%+7.69%+84.37%+103.14% 27.03B
Weighted average by Cap. -0.09%+7.39%+103.75%+136.43%

Financials

2026 *2027 *
Net sales 18.92M 16.4M 15.35M 14.01M 26.36M 1.81B 26.81M 180M 70.54M 903M 71.06M 69.51M 3.01B 19.14M 16.59M 15.53M 14.17M 26.66M 1.83B 27.11M 182M 71.34M 914M 71.86M 70.3M 3.05B
Net income -104M -89.87M -84.13M -76.76M -144M -9.89B -147M -986M -387M -4.95B -389M -381M -16.52B -150M -130M -122M -111M -210M -14.35B -213M -1.43B -561M -7.18B -565M -553M -23.96B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
12/08/26 $3.825 -1.16% 44,085
11/08/26 $3.870 +6.91% 3,085,427
10/08/26 $3.620 -2.95% 1,963,844
07/08/26 $3.730 +2.47% 1,504,081
06/08/26 $3.640 +0.55% 1,823,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.870USD
Average target price
13.33USD
Spread / Average Target
+244.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock